2. Search Result
Search Result
Pathways Recommended: Anti-infection
Results for "

anti-HIV-1 infection

" in MedChemExpress (MCE) Product Catalog:

28

Inhibitors & Agonists

1

Peptides

1

Inhibitory Antibodies

8

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-105231
    Bryostatin 1
    2 Publications Verification

    		 PKC HIV Bacterial Infection Neurological Disease Inflammation/Immunology Cancer
    Bryostatin 1 is a natural macrolide isolated from the bryozoan Bugula neritina and is a potent and central nervous system (CNS)-permeable PKC modulator. Bryostatin 1 binds to the isolated C1 domain of Munc13-1 and the full-length Munc13-1 protein with Kis of 8.07 nM and 0.45 nM, respectively. Bryostatin 1 has anti-cancer, anti-inflammatory, neuroprotective, anti-HIV-1 infection properties .
    Bryostatin 1
  • HY-78726
    Fosamprenavir
    4 Publications Verification

    Amprenavir phosphate; GW 433908

    		 Drug Intermediate HIV HIV Protease Infection
    Fosamprenavir is an orally active inhibitor targeting HIV-1 protease and is a prodrug of Amprenavir (HY-17430). Fosamprenavir is hydrolyzed into Amprenavir (VX-478) by cell phosphatases in the intestinal epithelium. Amprenavir binds to the active site of HIV-1 protease, preventing the processing of viral gag and gag-pol polyprotein precursors, thereby inhibiting the formation of mature infectious virus particles and exerting anti-HIV-1 infection activity. Fosamprenavir can be used for the study of human immunodeficiency virus (HIV-1) infection .
    Fosamprenavir
  • HY-173011
    RJS308

    		PROTACs Cyclophilin HIV HCV Infection
    RJS308 is a selective Cyclophilin A (CypA) PROTAC degrader. RJS308 induces ubiquitin-dependent CypA degradation by recruiting the VHL E3 ligase complex, and forms a ternary complex with CypA and VHL/elongin C/elongin B. RJS308 exhibits anti-HIV-1 and anti-HCV activities. RJS308 can be used in studies related to viral infections .
    RJS308
  • HY-17431
    Fosamprenavir Calcium Salt
    4 Publications Verification

    GW433908G

    		 Drug Intermediate HIV HIV Protease Infection
    Fosamprenavir Calcium Salt (GW433908G) is an orally active inhibitor targeting HIV-1 protease and is a prodrug of Amprenavir (HY-17430). Fosamprenavir Calcium Salt is hydrolyzed into Amprenavir (VX-478) by cell phosphatases in the intestinal epithelium. Amprenavir binds to the active site of HIV-1 protease, preventing the processing of viral gag and gag-pol polyprotein precursors, thereby inhibiting the formation of mature infectious virus particles and exerting anti-HIV-1 infection activity. Fosamprenavir Calcium Salt can be used for the study of human immunodeficiency virus (HIV-1) infection .
    Fosamprenavir Calcium Salt
  • HY-115488A
    BNM-III-170

    		HIV Infection
    BNM-III-170, CD4-mimeticcompound, is an anti-HIV-1 agent. BNM-III-170 binds to the Phe43 cavity of HIV 1 gp120. BNM-III-170 can inhibits HIV-1 viral entry into target cells. BNM-III-170 can be used for the research of HIV-1 infection .
    BNM-III-170
  • HY-173011A
    RJS308 TFA

    		PROTACs Cyclophilin HIV HCV Infection
    RJS308 TFA is a selective Cyclophilin A (CypA) PROTAC degrader. RJS308 TFA induces ubiquitin-dependent CypA degradation by recruiting the VHL E3 ligase complex, and forms a ternary complex with CypA and VHL/elongin C/elongin B. RJS308 TFA exhibits anti-HIV-1 and anti-HCV activities. RJS308 TFA can be used in studies related to viral infections .
    RJS308 TFA
  • HY-103078
    I-XW-053

    		HIV Reverse Transcriptase Infection
    I-XW-053 is a specific anti-HIV-1 capsid inhibitor (IC50=164.2 μM). By binding to the CA NTD-NTD hexamerization interface and the R173 region of CTD (Kd=66.3 μM), I-XW-053 disrupts capsid function and reduces polymerization levels. I-XW-053 effectively blocks HIV-1 uncoating, inhibits reverse transcription and early replication, and exhibits broad-spectrum activity against primary HIV-1 isolates in peripheral blood mononuclear cells. I-XW-053 can be widely used in studies related to HIV-1 infection .
    I-XW-053
  • HY-P99584
    Suvizumab

    KD-247

    		 HIV Infection
    Suvizumab (KD-247) is an neutralizing antibody anti-HIV-1. Suvizumab effectively neutralizes HIV-1MN, HIV-1SF2 and HIV-189.6 with IC50 values of 0.1 µg/mL, 1.0 µg/mL and 0.2 µg/mL, respectively. Suvizumab reduces the viral load of HIV. Suvizumab has good tolerance and can be used to prevent HIV infection .
    Suvizumab
  • HY-177437
    (±)-PM 92131

    		HIV Infection
    (±)-PM 92131 is a non-nucleoside HIV-1 inhibitor. (±)-PM 92131 has an anti-HIV-1 activity with IC50s of 45.7 and 53.8 μM for HIV-1 RF strain in XTT cytoprotection and syncytium-forming assay, respectively. (±)-PM 92131 can be used for HIV infections research .
    (±)-PM 92131
  • HY-177437A
    (+)-PM 92131

    		HIV Infection
    (+)-PM 92131 is the active enantiomer of (±)-PM 92131 (HY-177437). (+)-PM 92131 is a non-nucleoside HIV-1 inhibitor. (+)-PM 92131 has an anti-HIV-1 activity with EC50s of 0.8 and 0.6 μM for HIV-1 RF strain in XTT cytoprotection and syncytium-forming assay, respectively. (+)-PM 92131 can be used for HIV infections research .
    (+)-PM 92131
  • HY-78726S
    Fosamprenavir-d4

    Amprenavir phosphate-d4; GW 433908-d4

    		 Isotope-Labeled Compounds Drug Intermediate HIV HIV Protease Infection
    Fosamprenavir-d4 is the Deuterium-labeled Fosamprenavir (HY-78726). Fosamprenavir is an orally active inhibitor targeting HIV-1 protease and is a prodrug of Amprenavir (HY-17430). Fosamprenavir is hydrolyzed into Amprenavir (VX-478) by cell phosphatases in the intestinal epithelium. Amprenavir binds to the active site of HIV-1 protease, preventing the processing of viral gag and gag-pol polyprotein precursors, thereby inhibiting the formation of mature infectious virus particles and exerting anti-HIV-1 infection activity. Fosamprenavir can be used for the study of human immunodeficiency virus (HIV-1) infection .
    Fosamprenavir-d4
  • HY-103078A
    I-XW-053 sodium

    		HIV Reverse Transcriptase Infection
    I-XW-053 sodium is a specific anti-HIV-1 capsid inhibitor (IC50=164.2 μM). By binding to the CA NTD-NTD hexamerization interface and the R173 region of CTD (Kd=66.3 μM), I-XW-053 sodium disrupts capsid function and reduces polymerization levels. I-XW-053 sodium effectively blocks HIV-1 uncoating, inhibits reverse transcription and early replication, and exhibits broad-spectrum activity against primary HIV-1 isolates in peripheral blood mononuclear cells. I-XW-053 sodium can be widely used in studies related to HIV-1 infection .
    I-XW-053 sodium
  • HY-172603
    HIV-1-IN-82

    		HIV Infection
    HIV-1-IN-82 (Compound L14) is an orally active small-molecule entry inhibitor for HIV-1 with an IC50 value of 0.39 μM. HIV-1 inhibitor-82 is promising for research of anti-HIV-1 infection .
    HIV-1-IN-82
  • HY-179348
    DPP9-IN-2

    		Dipeptidyl Peptidase HIV Pyroptosis Cancer
    DPP9-IN-2 is a selective, potent and orally active inhibitor of Dipeptidyl Peptidase 9 (DPP9 ) with an IC50 of 12.9 nM. DPP9-IN-2 shows a SI of 59 over DPP8, and shows no significant inhibitory activity against related peptidases including DPP2, DPP4, FAP, and PREP. DPP9-IN-2 can induce cancer cells pyroptosis and has weak synergistic anti-HIV-1 activity when combined with non-nucleoside reverse transcriptase inhibitor. DPP9-IN-2 can be used for the researches of cance rand infection .
    DPP9-IN-2
  • HY-P11037
    soVIRIP

    		HIV Infection
    soVIRIP is a virus inhibitory peptide with an IC50 of 1.2  μM for HIV-1 . soVIRIP binds to the HIV-1 GP41 fusion peptide and inhibits viral fusion and entry into host cells. soVIRIP has broad-spectrum anti-HIV-1 activities with nontoxicity in zebrafish models. soVIRIP can used for viral infections research .
    soVIRIP
  • HY-78726A
    Fosamprenavir sodium

    Amprenavir phosphate sodium; GW 433908 sodium

    		 Drug Intermediate HIV HIV Protease Infection
    Fosamprenavir sodium is an orally active inhibitor targeting HIV-1 protease and is a prodrug of Amprenavir (HY-17430). Fosamprenavir sodium is hydrolyzed into Amprenavir (VX-478) by cell phosphatases in the intestinal epithelium. Amprenavir binds to the active site of HIV-1 protease, preventing the processing of viral gag and gag-pol polyprotein precursors, thereby inhibiting the formation of mature infectious virus particles and exerting anti-HIV-1 infection activity. Fosamprenavir sodium can be used for the study of human immunodeficiency virus (HIV-1) infection .
    Fosamprenavir sodium
  • HY-78726S2
    Fosamprenavir-13C6

    Amprenavir phosphate-13C6; GW 433908-13C6

    		 Isotope-Labeled Compounds Drug Intermediate HIV HIV Protease Infection
    Fosamprenavir- 13C6 is the 13C-labeled Fosamprenavir (HY-78726). Fosamprenavir is an orally active inhibitor targeting HIV-1 protease and is a prodrug of Amprenavir (HY-17430). Fosamprenavir is hydrolyzed into Amprenavir (VX-478) by cell phosphatases in the intestinal epithelium. Amprenavir binds to the active site of HIV-1 protease, preventing the processing of viral gag and gag-pol polyprotein precursors, thereby inhibiting the formation of mature infectious virus particles and exerting anti-HIV-1 infection activity. Fosamprenavir can be used for the study of human immunodeficiency virus (HIV-1) infection .
    Fosamprenavir-13C6
  • HY-17431R
    Fosamprenavir Calcium Salt (Standard)

    GW433908G (Standard)

    		 Reference Standards Drug Intermediate HIV HIV Protease Infection
    Fosamprenavir Calcium Salt (GW433908G) (Standard) is the analytical standard of Fosamprenavir Calcium Salt (HY-17431R). This product is intended for research and analytical applications. Fosamprenavir Calcium Salt (GW433908G) is an orally active inhibitor targeting HIV-1 protease and is a prodrug of Amprenavir (HY-17430). Fosamprenavir Calcium Salt is hydrolyzed into Amprenavir (VX-478) by cell phosphatases in the intestinal epithelium. Amprenavir binds to the active site of HIV-1 protease, preventing the processing of viral gag and gag-pol polyprotein precursors, thereby inhibiting the formation of mature infectious virus particles and exerting anti-HIV-1 infection activity. Fosamprenavir Calcium Salt can be used for the study of human immunodeficiency virus (HIV-1) infection .
    Fosamprenavir Calcium Salt (Standard)
  • HY-N17741
    Melanochromone

    		HIV Reverse Transcriptase Infection
    Melanochromone is an HIV-1 reverse transcriptase inhibitor that exhibits anti-HIV-1 activity. Melanochromone can be used in research related to HIV-1 infection .
    Melanochromone
  • HY-N19826
    Lancifodilactone N

    		HIV Infection
    Lancifodilactone N is a nortriterpenoid found in the leaves and stems of Schisandra lancifolia. Lancifodilactone N shows anti-HIV-1 activity and can be used for the research of HIV-1 infection .
    Lancifodilactone N
  • HY-117205
    GS-7339

    		HIV Infection
    GS-7339 is a diastereomer of GS-7171 (HY-136555) and is an anti-HIV-1 agent with an IC50 of 0.06 μM. GS-7339 can be used for the research of HIV-1 infection .
    GS-7339
  • HY-N16821
    Hydroxydihydrobovolide

    		HIV Infection Neurological Disease
    Hydroxydihydrobovolide is a α-β-unsaturatedγ-lactone found in Portulaca oleracea L.. Hydroxydihydrobovolide shows cytotoxicity against cancer cells and shows anti-HIV-1 activity (IC50 = 122.7 μM). Hydroxydihydrobovolide can be used for the researches of neuroblastoma and HIV-1 infection .
    Hydroxydihydrobovolide
  • HY-182376
    JRC-I-191

    		HIV Infection
    JRC-I-191 is an anti-HIV-1 agent. JRC-I-191 inhibits HIV-1 YU-2 entry into cells. JRC-I-191 does not inhibit infection of cells by amphotropic murine leukemia virus. JRC-I-191 can be used for the research of HIV-1 infection .
    JRC-I-191
  • HY-182514
    BMMP

    		HIV hnRNP Infection Cancer
    BMMP is an anti-HIV-1 agent and hnRNP M modulator. BMMP modulates hnRNP M function to suppress CD44 mRNA expression. BMMP induces abnormal uncoating of the HIV viral core at the post-entry step. BMMP suppresses migration of TGF-β-stimulated lung carcinoma cells. BMMP suppresses HIV-1 reverse transcription and replication without inhibiting virion release. BMMP exerts anti-HIV-1 activity via a mechanism distinct from CA protein-binding heterocyclic compounds. BMMP can be used for the research of human immunodeficiency virus infection and non-small cell lung cancer .
    BMMP
  • HY-115488
    BNM-III-170 free base

    		HIV Infection
    BNM-III-170 free base, CD4-mimeticcompound, is an anti-HIV-1 agent. BNM-III-170 free base, binds to the Phe43 cavity of HIV 1 gp120. BNM-III-170 can inhibits HIV-1 viral entry into target cells. BNM-III-170 free base, can be used for the research of HIV-1 infection .
    BNM-III-170 free base
  • HY-N17718
    Urushiol (15:3)

    3-[8'(Z), 11'(Z), 14'-Pentadecatrienyl] catechol

    		 HIV Reverse Transcriptase Infection Cancer
    Ursolic acid (15:3) (Compound 4) is a type of resiniferatoxin compound that can be found in the leaves of the tree Rhus verniciflua. Ursolic acid (15:3) exhibits moderate inhibitory activity against HIV-1 reverse transcriptase (b HIV-1 reverse transcriptase), with an IC50 value of 55.36 μM. Ursolic acid (15:3) shows strong cytotoxicity against both PC-3 and MRC-5 cells. Ursolic acid (15:3) can be used in the research of anti-HIV-1 infection and prostate cancer .
    Urushiol (15:3)
  • HY-183925
    Redoxal

    		HIV Dihydroorotate Dehydrogenase Infection
    Redoxal is a dihydroorotate dehydrogenase (DHODH) inhibitor and anti-HIV-1 agent. Redoxal induces intracellular pyrimidine depletion by inhibiting the de novo pyrimidine biosynthesis pathway, enhances the protein stability of APOBEC3G (A3G), upregulates the abundance of A3G protein in cells and progeny viral particles, thereby strengthening the host endogenous antiviral restriction mediated by A3G . Redoxal selectively targets DHOdehase at the mitochondrial level, with an IC50 of 430 nM for inhibiting DHO oxidation in human mitochondria and an IC50 of 910 nM in rat mitochondria . Redoxal can be used in studies related to HIV-1 infection .
    Redoxal
  • HY-103078R
    I-XW-053 (Standard)

    		Reference Standards HIV Reverse Transcriptase Infection
    I-XW-053 (Standard) is the analytical standard of I-XW-053 (HY-103078). This product is intended for research and analytical applications. I-XW-053 is a specific anti-HIV-1 capsid inhibitor (IC50=164.2 μM). By binding to the CA NTD-NTD hexamerization interface and the R173 region of CTD (Kd=66.3 μM), I-XW-053 disrupts capsid function and reduces polymerization levels. I-XW-053 effectively blocks HIV-1 uncoating, inhibits reverse transcription and early replication, and exhibits broad-spectrum activity against primary HIV-1 isolates in peripheral blood mononuclear cells. I-XW-053 can be widely used in studies related to HIV-1 infection .
    I-XW-053 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: